Literature DB >> 1733645

Myeloma affects both the growth and function of human osteoblast-like cells.

C E Evans1, C Ward, L Rathour, C B Galasko.   

Abstract

Myeloma behaves differently to other osteolytic tumours which metastasize to bone, in that the latter usually provoke reactive bone formation in the host bone. A previous study showed that a myeloma cell line (GM1500) secreted an osteoblast-inhibiting factor(s). The present study was undertaken to determine whether other myeloma cells also secreted a factor(s) which inhibited both cell proliferation and DNA synthesis of osteoblast-like cells and whether the myeloma also affected the function of osteoblasts. The results showed that a second cell line (Karpas 707) as well as myeloma tissue taken from two patients had a similar effect. The myeloma cells did not affect total collagen or protein synthesis, and did not affect the overall degree of mineralization. A biphasic effect was seen on alkaline phosphatase activity. Thus, although the proliferation of the pre-osteoblast was affected, the synthetic functions of the osteoblasts were not.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733645     DOI: 10.1007/bf00163574

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  17 in total

1.  Response of bone to tumor invasion.

Authors:  R A MILCH; G W CHANGUS
Journal:  Cancer       Date:  1956 Mar-Apr       Impact factor: 6.860

2.  Downregulation of cell growth and cell cycle regulated genes during chick osteoblast differentiation with the reciprocal expression of histone gene variants.

Authors:  V Shalhoub; L C Gerstenfeld; D Collart; J B Lian; G S Stein
Journal:  Biochemistry       Date:  1989-06-27       Impact factor: 3.162

3.  Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations.

Authors:  C G Bellows; J E Aubin; J N Heersche; M E Antosz
Journal:  Calcif Tissue Int       Date:  1986-03       Impact factor: 4.333

4.  Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins.

Authors:  B Peterkofsky; R Diegelmann
Journal:  Biochemistry       Date:  1971-03-16       Impact factor: 3.162

5.  Characterization of cells with high alkaline phosphatase activity derived from human bone and marrow: preliminary assessment of their osteogenicity.

Authors:  B A Ashton; F Abdullah; J Cave; M Williamson; B C Sykes; M Couch; J W Poser
Journal:  Bone       Date:  1985       Impact factor: 4.398

6.  Formation of bone by isolated, cultured osteoblasts in millipore diffusion chambers.

Authors:  D J Simmons; G N Kent; R L Jilka; D M Scott; M Fallon; D V Cohn
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

7.  Does myeloma secrete an osteoblast inhibiting factor?

Authors:  C E Evans; C S Galasko; C Ward
Journal:  J Bone Joint Surg Br       Date:  1989-03

8.  Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.

Authors:  B G Durie; S E Salmon; G R Mundy
Journal:  Br J Haematol       Date:  1981-01       Impact factor: 6.998

9.  Mechanisms of lytic and blastic metastatic disease of bone.

Authors:  C S Galasko
Journal:  Clin Orthop Relat Res       Date:  1982-09       Impact factor: 4.176

10.  Human myeloma cell line carrying a Philadelphia chromosome.

Authors:  A Karpas; P Fischer; D Swirsky
Journal:  Science       Date:  1982-05-28       Impact factor: 47.728

View more
  6 in total

Review 1.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 2.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Bone Disease in Multiple Myeloma: Biologic and Clinical Implications.

Authors:  Zachary S Bernstein; E Bridget Kim; Noopur Raje
Journal:  Cells       Date:  2022-07-27       Impact factor: 7.666

Review 4.  Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Authors:  Fabrizio Accardi; Denise Toscani; Marina Bolzoni; Benedetta Dalla Palma; Franco Aversa; Nicola Giuliani
Journal:  Biomed Res Int       Date:  2015-10-22       Impact factor: 3.411

5.  NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.

Authors:  Michelle A Lawson; Julia M Paton-Hough; Holly R Evans; Rebecca E Walker; William Harris; Dharshi Ratnabalan; John A Snowden; Andrew D Chantry
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

Review 6.  Role of Polycomb Complexes in Normal and Malignant Plasma Cells.

Authors:  Emmanuel Varlet; Sara Ovejero; Anne-Marie Martinez; Giacomo Cavalli; Jerome Moreaux
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.